endorsed abdominal pain and lightheadedness secondary to dehydration but denied any fever, coryza, change in bowel movements, or sick contacts.
The patient had been experiencing similar episodes recurrently for the past two years, frequently associated with life stressors and requiring five previous hospitalizations. He had received an extensive work-up, including laboratory tests, KUB, CT abdomen, abdominal ultrasound, gastric emptying study, and EGD. All tests returned negative for identifiable pathology, with the exception of electrolyte disturbances secondary to protracted emesis. As a result, the patient was diagnosed with cyclic vomiting syndrome.
Notably, however, the patient had been an intermittent, recreational marijuana user for many years prior but had escalated to daily use over the past two years for symptom relief, citing cannabis's known antiemetic effects. In addition, he described a compulsive pattern of bathing, stating that he often felt nauseated when having bowel movements and had discovered that transitioning directly from the toilet to a hot shower helped resolve his nausea. He described turning the shower temperature to a maximum, noting that it felt as though the hot water washed away his nausea. The patient often required several such showers per day and had been doing this for at least one year. predominance of symptoms, normal bowel habits, and negative laboratory, radiographic, and endoscopic test results. In addition to these features, it has also been noted that many patients report autonomic symptoms such as flushing and diaphoresis. 3 The compulsive bathing seen in CHS is a pattern not noted in other vomiting disorders and is thus hypothesized to be a pathognomonic feature. Symptom relief from bathing appears to be temperature-dependent, with hotter water yielding more effective relief. This bathing behavior is not considered psychotic or obsessive-compulsive but is instead learned: often absent during initial episodes of nausea and vomiting, it rapidly becomes a compulsion once symptom relief is established, disappears during intervening periods of normal health, and resolves fully with cessation of cannabis use. 2 Notably, cyclic vomiting due to CHS has been suggested to be refractory to common antiemetics; thus, hot water bathing is often the only alleviating factor patients can recognize. use, a urine drug screen is warranted, as these behaviors may be considered pathognomonic for CHS. 4 In pursuing these lines of evaluation, the patient and provider can come to the appropriate diagnosis more quickly, with reduction in patient morbidity and use of health care resources.
Treatment for CHS is supportive, with cannabis cessation and fluid replacement if clinically indicated. 4 Various theories have been proposed to explain the pathophysiology of CHS, employing both the pharmacokinetics and pharmacodynamics of cannabinoids. First, delta 9-tetrahydrocannabinol (THC), the main active compound in cannabis, has a tendency to sequester in fat with slow rediffusion back into the serum. This tendency seems to create different phases of excretion with the rate of elimination slowing in each successive phase: a half-life of approximately two hours has been measured in the first eight hours after administration, but a half-life of up to 12.6 days has been measured when the observation period is extended to four weeks. 6 Thus, THC's large volume of distribution may lead to accumulation in chronic users and potential toxicity in predisposed patients. with CB 1 receptors in the CNS and GI tract being implicated in most of cannabis's known effects.
THC activates CB 1 receptors in the enteric nervous system to decrease gastric motility, which would incline toward nausea and vomiting. However, THC also exerts a variety of antiemetic effects centrally at the brainstem dorsal vagal complex: it activates CB 1 receptors, 5 noncompetitively inhibits 5-HT 3 serotonin receptors (the target of 5-HT 3 antagonists such as ondansetron), and potentially also inhibits serotonin release via pre-synaptic CB 1 receptors. 7 This central action is postulated to outweigh THC's pro-emetic effect on the GI tract since cannabis use is not traditionally associated with nausea and vomiting. 5 Given this extensive central antiemetic action, it is difficult to determine how some chronic cannabis users develop CHS. Some authors have suggested that THC's pro-emetic effect in the gut outweighs its central antiemetic effect in susceptible individuals. 5 However, of the 61 patients in the Mayo Clinic case series who received gastric scintigraphy, 46% had normal gastric emptying, 30% had delayed emptying, and 25% had rapid emptying. 3 Impaired gastric motility thus does not appear to be a consistent factor in patients with CHS. Other authors have suggested that different compounds in cannabis, namely cannabidiol and cannabigerol, may mediate the pathogenesis of CHS. 5 Interestingly, cannabidiol, the principal non-psychoactive component of marijuana, has been found to have a biphasic effect on vomiting in shrews. In both cis-platinum and lithium-treated shrews, low doses of cannabidiol suppressed vomiting, but high doses potentiated vomiting. In contrast, THC had a dose-dependent antiemetic effect in both Finally, though the pathophysiology of the compulsive bathing distinctive to CHS is not yet well-understood, the prevailing theory suggests that cannabis toxicity may lead to impaired thermoregulation, with hot water bathing acting to relieve decreases in core body temperature. 3 Indeed, in rodents the hypothermic effect of THC is well-established: acting via hypothalamic CB 1 receptors, THC induces dose-dependent hypothermia that is reversible upon administration of CB 1 antagonists. 9, 10 Interestingly, the SSRI fluoxetine has been shown to modulate this action by attenuating hypothermia when fluoxetine administration precedes that of THC but potentiating hypothermia when fluoxetine follows THC. 11 This finding is particularly intriguing as our patient was also regularly taking an SSRI, citalopram. Given the interaction of cannabinoids with the serotonergic system and given the frequent concomitance of substance use and mood disorders (which can both disrupt the serotonergic system independently and lead to administration of psychotropic medications), one might hypothesize that derangements in the serotonergic system could predispose to development of CHS. For instance, the inhibitory effects of THC on serotonin release and its concurrent 5-HT 3 receptor blockade could lead to upregulation of 5-HT 3 receptors in susceptible chronic users, perhaps causing paradoxically increased sensitivity to emetogenic stimuli either with administration of medications that increase serotonin availability or with temporary cessation of cannabis use.
Summary:
Iacopetti 
